M. Witzenrath (Berlin, Germany), A. Shah (London, United Kingdom)
Late Breaking Abstract - Efficient replication of respiratory syncytial virus induces a decrease of mucociliary clearance in human small airway 3D culture
S. Huang (Plan les Ouates, Switzerland), B. Boda (Plan les Ouates, Switzerland), R. Bonfante (Plan les Ouates, Switzerland), J. Vernaz (Plan les Ouates, Switzerland), P. Alouani (Plan les Ouates, Switzerland), S. Constant (Plan les Ouates, Switzerland)
|   |
Late Breaking Abstract - Multidimensional genomic mapping reveals the pathophysiology of Mycobacterium abscessus
L. Boeck (Cambridge, United Kingdom), M. Skwark (Cambridge, United Kingdom), W. Pearson (London, United Kingdom), S. Burbaud (Cambridge, United Kingdom), J. Sangen (Cambridge, United Kingdom), S. Malhotra (Cambridge, United Kingdom), J. Bryant (Cambridge, United Kingdom), T. Blundell (Cambridge, United Kingdom), M. Dionne (London, United Kingdom), J. Parkhill (Cambridge, United Kingdom), A. Floto (Cambridge, United Kingdom)
|   |
Airway administration of therapeutic antibody (tAb) confers higher protection than parenteral administration in a murine model of acute lung infection
T. Secher (Tours, France), E. Dalonneau (Tours, France), C. Parent (Tours, France), N. Heuzé-Vourc'H (Tours, France)
| |
EPs®7630 reduced Rhinovirus bronchial epithelial cell infection and modified host defence systems
M. Roth (Basel, Switzerland), L. Fang (Basel, Switzerland), D. Stolz (Basel, Switzerland), M. Tamm (Basel, Switzerland)
| |
Therapeutic intratracheal phage application against Acinetobacter baumannii lung infection in mice
S. Wienhold (Berlin, Germany), M. Brack (Berlin, Germany), G. Nouailles (Berlin, Germany), C. Seitz (Braunschweig, Germany), A. Ross (Braunschweig, Germany), H. Ziehr (Braunschweig, Germany), K. Dietert (Berlin, Germany), C. Gurtner (Berlin, Germany), O. Kershaw (Berlin, Germany), A. Gruber (Berlin, Germany), M. Rohde (Braunschweig, Germany), N. Suttorp (Berlin, Germany), C. Rohde (Braunschweig, Germany), M. Witzenrath (Berlin, Germany)
| |
Intrapulmonary pharmacokinetics of laninamivir in healthy subjects: Comparison between a nebulizer and a dry powder inhaler
H. Ishizuka (Tokyo, Japan), H. Furuie (Osaka, Japan), K. Toyama (Tokyo, Japan)
| |
Streptococcus pneumoniae inhibits Pseudomonas aeruginosa growth on nasal human epithelium in vitro
S. Huang (Plan les ouates, Switzerland), C. Bertinetti (Plan les ouates, Switzerland), O. Verbeke (Plan les ouates, Switzerland), M. Caul-Futy (Plan les ouates, Switzerland), P. Alouani (Plan les ouates, Switzerland), L. Wiszniewski (Plan les ouates, Switzerland), S. Constant (Plan les ouates, Switzerland)
| |
The biological effect of intrapleural tissue plasminogen (tPA) activator and DNase delivery in pleural infection patients.
N. Kanellakis (Oxford, United Kingdom), J. Wrightson (Oxford, United Kingdom), R. Hallifax (Oxford, United Kingdom), R. Mercer (Oxford, United Kingdom), M. Fayed (Oxford, United Kingdom), R. Asciak (Oxford, United Kingdom), I. Psallidas (Oxford, United Kingdom), N. Rahman (Oxford, United Kingdom)
| |
Telavancin vs. linezolid in an animal model of severe MRSA pneumonia
D. Battaglini (Genova, Italy), G. Li Bassi (Barcelona, Spain), F. Pagliara (Genova, Italy), A. Meli (Milano, Italy), H. Yang (Barcelona, Spain), M. Yang (Barcelona, Spain), A. Motos (Barcelona, Spain), J. Bobi (Barcelona, Spain), E. Aguilera (Barcelona, Spain), T. Senussi (Genova, Spain), J. Miller (Barcelona, Spain), L. Fernandez (Barcelona, Spain), E. Barbeta Viñas (Barcelona, Spain), A. Torres (Barcelona, Spain)
| |
Experimental investigation of pulmonary Aspergillus infection in type 1 diabetes
Y. Ye (Shenyang, China), W. Li (Shenyang, China), W. Wang (Shenyang, China)
| |
MAIT cells contribute to a protective antiviral innate response to influenza infection
T. Hinks (Oxford, United Kingdom), B. Van Wilgenburg (Oxford, United Kingdom), L. Loh (Melbourne, Australia), Z. Chen (Melbourne, Australia), T. Pediongco (Melbourne, Australia), H. Wang (Melbourne, Australia), M. Shi (Melbourne, Australia), Z. Zhao (Melbourne, Australia), M. Koutsakos (Melbourne, Australia), S. Nussing (Melbourne, Australia), S. Sant (Melbourne, Australia), Z. Wang (Melbourne, Australia), C. D'Souza (Melbourne, Australia), C. Almeida (Melbourne, Australia), P. Reading (Melbourne, Australia), A. Corbett (Melbourne, Australia), J. Mccluskey (Melbourne, Australia), P. Klenerman (Oxford, United Kingdom), K. Kedzierska (Melbourne, United Kingdom)
| |
Tolerability of anti-infective N-chlortaurine inhaled with a smart-nebuliser
R. Arnitz (Vöcklabruck, Austria), M. Stein (Natters, Austria), P. Bauer (Natters, Austria), B. Lanthaler (Innsbruck, Austria), H. Jamnig (Natters, Austria), S. Scholl-Bürgi (Innsbruck, Austria), K. Stempfl-Al-Jazrawi (Innsbruck, Austria), H. Ulmer (Innsbruck, Austria), B. Baumgartner (Vöcklabruck, Austria), S. Embacher (Natters, Austria), S. Geisler (Innsbruck, Austria), J. Gostner (Innsbruck, Austria), B. Müllinger (Gauting, Germany), B. Kälz (Neufeld, Austria), M. Nagl (Innsbruck, Austria)
| |
The role of CARD9 in Pneumocystis host defense
J. Chae (Rochester, MN, United States of America), V. Nandakumar (Rochester, MN, United States of America), D. Hebrink (Rochester, MN, United States of America), T. Kottom (Rochester, MN, United States of America), A. Limper (Rochester, MN, United States of America)
| |
High-dose nitric oxide as a potential new therapeutic agent against Mycobacterium abscessus.
A. Ghaffari (Harrison, NY, United States of America), J. Da Silva (Bethesda, MD, United States of America), K. Bogdanovski (Bethesda, MD, United States of America), A. Zelazny (Bethesda, MD, United States of America), K. Olivier (Bethesda, MD, United States of America)
| |
Pattern of self-reported (cough focus) symptoms across several respiratory virus- human challenge studies
A. Bell (London, United Kingdom), M. Ghebre (London, United Kingdom), G. Clarke (London, United Kingdom), R. Lambkin Williams (London, United Kingdom), A. Catchpole (London, United Kingdom), N. Noulin (London, United Kingdom)
| |
Impact of age and gender on efficacy and safety of omadacycline (OMC) vs. moxifloxacin (MOX) in community-acquired bacterial pneumonia (CABP)
J. Ramirez (Louisville, KY, United States of America), L. Garrity-Ryan (King of Prussia, PA, United States of America), S. Chitra (King of Prussia, PA, United States of America), C. Kirsch (King of Prussia, PA, United States of America), A. Manley (King of Prussia, PA, United States of America), E. Tzanis (King of Prussia, PA, United States of America), P. Mcgovern (King of Prussia, PA, United States of America)
| |